Objective: Super-refractory status epilepticus (SRSE) is a severe condition in which a patient in status epilepticus (SE) for ≥24 h does not respond to first-, second-, or thirdline therapy. The economic impact of SRSE treatment remains unclear. A health insurance research database was used for a population-based estimation of SRSE-associated inpatient costs, length of stay, and mortality in Germany. Methods: An algorithm using International Classification of Diseases, 10th Edition coding and treatment parameters identified and classified patients in a German statutory health insurance database covering admissions from 2008 to 2013 as having refractory SE (RSE) or SRSE. Admissions data in our study refer to these classifications. Associated patient data included costs, procedures, and demographics. Results: The algorithm identified 2,585 (all type) SE admissions, classified as 1,655 nonrefractory SE (64%), 592 (22.9%) RSE, and 338 (13.1%) SRSE, producing database incidence rates of 15.0 in 100,000, 5.2 in 100,000, and 3.0 in 100,000 per year, respectively. Median cost per admission was €4,063 for nonrefractory SE, €4,581 (p < 0.001) for RSE, and €32,706 (p < 0.001) for SRSE. Median length of stay varied significantly between 8 days (mean = 13.6) in nonrefractory SE, 14 days in RSE, and up to 37 days in SRSE. Discharge mortality increased from 9.6% in nonrefractory SE to 15.0% (p < 0.001) in RSE and 39.9% (p < 0.001) in SRSE. Significance: This study evaluated the hospital treatment costs associated with admissions classified by the algorithm as SRSE in Germany. SRSE represented 13% of all SE admissions, but resulted in 56% of all SE-related costs. The lack of approved treatments and limited number of evidence-based treatment guidelines highlight the need for further evaluations of the SRSE burden of illness and the potential for further optimization of treatments for SRSE.
Status epilepticus (SE) is a life-threatening, acute neurological condition associated with high mortality and morbidity. The 2015 International League Against Epilepsy (ILAE) guidelines define SE as a seizure lasting >5 min (generalized convulsive SE), ≥10 min (focal SE), or repeated seizures that do not permit recovery to baseline between events. 1 If left untreated, SE can lead to profound long-term effects through excitotoxic neuronal injury or death and alternation of neuronal networks. Accordingly, shorter times to treatment are associated with better outcomes.
Initial treatment consists of administration of a benzodiazepine 2,4 by emergency medical services or an emergency department, and care of SE patients quickly transfers to intensive care units (ICUs) . If the initial benzodiazepine treatment and subsequent treatment with intravenous antiepileptic drugs (AEDs) such as phenytoin, levetiracetam, valproate, or lacosamide fail to stop the seizures, the patient is defined as having refractory SE (RSE), 5 which is treated with third-line anesthetic agents, such as propofol, high-dose midazolam, or barbiturates. These treatments typically quell the seizure activity, but in some patients, seizures persist or recur upon withdrawal of third-line anesthetics. These superrefractory SE (SRSE) patients are defined by SE that persists for 24 h or more despite treatment with thirdline anesthetic agents, or persists after the weaning of third-line anesthetic agents. 5, 6 SE can develop as a result of many events, including brain trauma, stroke, tumors, infection, substance abuse, or medications with proconvulsive profiles, 5, 7 and the mechanisms underlying the progression from SE to RSE to SRSE are not entirely clear. However, it is clear that SE becomes less responsive to AEDs over time, and the lack of responsiveness observed in SRSE may be due to multiple factors, including loss of c-aminobutyric acid (GABA)-mediated inhibition, GABA receptor trafficking, and upregulation of excitatory receptors. 8 The incidence of SE has been estimated from 11 in 100,000 to 61 in 100,000 using a variety of different methodologies, regions, and populations. [9] [10] [11] [12] [13] [14] [15] A prior population-based study in Germany provided an incidence rate of 17.1 in 100,000. 15 Prior predictions have suggested that 10-15% of SE admissions evolve into SRSE, 6 and a few small studies have examined the incidence rates for RSE and SRSE, finding that approximately 5-17% of SE admissions progress to SRSE. 7, [16] [17] [18] SRSE is associated with significant morbidity and mortality, but there is currently no consensus mortality rate, with reported mortality rates ranging 35-43%. 6, 13, 18, 19 Additionally, more than half of the patients who recover from SRSE exhibit cognitive defects. 5, 6, 10, 19 Notably, the number of days in a medically induced coma correlates with poor prognosis and decreased cognitive functionality. 20 Data on the economic costs associated with SE, RSE, and SRSE are similarly limited. Only three studies have addressed the costs of SE, and no previous studies have addressed the costs of RSE or SRSE in Germany. 21 To further characterize the incidence, inpatient resource use, and costs of SRSE in Germany, including length of stay and mortality, we analyzed the Gesundheitsforen Leipzig research database of statutory health insurance data from 2008 to 2013.
Methods

Data source
This retrospective analysis utilized the Gesundheitsforen Leipzig research database, which contains data from approximately 4.1 million patients across all of Germany (approximately 5.1% of the German population) covered by statutory health insurance (Gesetzliche Krankenversicherung). All data in this database are deidentified, and the study was granted approval by the institutional review board of the University of Frankfurt. The database contains inpatient diagnoses, outpatient diagnoses, costs, procedures, and demographics for pediatric and adult patients. Entries are regularly collected and routinely inspected for outliers, data errors, and longitudinal changes. The database is continuously evaluated to ensure that it is representative of the German population by comparison to the annual publications of the German Federal Social Insurance Office (Bundesversicherungsamt) and has been used previously for epidemiological studies in epilepsy and multiple sclerosis. 22, 23 Outcome assessment
The cost of illness of SRSE was assessed using a topdown approach from the perspective of the statutory health insurer on all hospitalization admissions between 2008 and 2013. Length of stay and mortality at discharge were calculated from the database. The costs were calculated in Euros (€) and reflect all costs for which hospitals were reimbursed, which are largely based on German Diagnosis Related Groups (DRG; www.g-drg.de). 23 
Identification of potential SE admissions
Potential SE admissions were identified using the presence of 10th revision of the International Statistical Classification of Diseases and Related Health Problems, German Modification, (ICD-10-GM; www.dimdi.de) codes for SE (G41*) or epilepsy (G40*; Fig. 1 ). As there are no significant differences in SE and epilepsy codes between the ICD-10 and ICD-10-GM systems at the third-or fourth-digit level, the term ICD-10 is used throughout this article. Similar processes of epilepsy admission identification were used in previous Canadian and German evaluations based on ICD-10 coding, and these studies demonstrated sensitivity and positive predictive value of up to 98%. [23] [24] [25] [26] [27] [28] All admissions with a primary or secondary SE diagnosis (G41*), or a primary epilepsy diagnosis (G40*), were chosen for further classification as per the algorithm.
Each admission was further classified depending on admission to an ICU, use of mechanical ventilation, and type of diagnosis ( Fig. 1 Duration of ventilation and duration of ICU stays were calculated from procedure codes (Operationen-und Prozedurenschl€ ussel [OPS] ) and DRG (see supplemental material for a full list). Each admission was evaluated as an independent event. The NRSE, RSE, and SRSE groups were defined to be mutually exclusive (Fig. 1 ).
Secondary admission classification
Determination of SE etiology and onset
All admissions identified as SE (NRSE, RSE, and SRSE) using the algorithm were further classified according to primary diagnosis, prior epilepsy history, and evidence for resuscitation. Epilepsy history was determined by the occurrence of G40 diagnoses up to 1 year prior to the hospitalization admission.
This secondary classification resulted in categorization of admissions into five SE admission types determined by etiology:
Type 1-SE with previous history of epilepsy: current G40 and G41 diagnoses with prior epilepsy Type 2-New onset SE with no previous history of epilepsy or SE within the past year: current G40 and G41 diagnoses without prior epilepsy Type 3-Acute symptomatic SE due to an acute brain injury as defined by the ILAE: G41 diagnosis, no resuscitation Type 4-Hypoxic SE: secondary G41 diagnosis and resuscitation; resuscitation was identified by OPS, DRG (see appendix), and ICD-10 coding of cardiac arrest (I46*) Type 0-SE with unclear epilepsy history due to limited database information: patients with a G40/G41 current primary diagnosis and no history of prior epilepsy; however, patient history was available for <1 year.
Statistical analysis
All analyzed data were deidentified. All data were analyzed with SQL Server 2008 R2 and Microsoft Excel. To estimate the yearly occurrence of NRSE, RSE, and SRSE admissions in hospitals, each admission from the pooled dataset was assigned to the calendar year in which the admission took place. The algorithm does not mandate that each admission be a unique patient. The annual database incidence rates of admissions from 2008 to 2013 were estimated for epilepsy, NRSE, RSE, and SRSE by dividing the number of admissions per year classified in each group using the algorithm by the number of total patients in the entire database for each year. Chi-square tests were performed to assess the significance of the distribution of discharge destinations. The median and mean costs, length of Algorithm for categorization of nonrefractory status epilepticus (NRSE), refractory status epilepticus (RSE), and super-refractory status epilepticus (SRSE). E, epilepsy; ICU, intensive care unit. Epilepsia ILAE stay, and mechanical ventilation times were calculated per admission for all SE-associated inpatient treatments, including NRSE, RSE, and SRSE, during the evaluation period. Probability values were determined by the Mann-WhitneyWilcoxon test, comparing RSE to NRSE or SRSE to NRSE. The cost data are presented as mean AE standard deviation (SD) and minimum, maximum, median, or percentages where appropriate. A univariate analysis of costs was performed, and patients were not matched based on underlying etiology or comorbidities.
Results
Characteristics of patients with SE
During the 6-year study period, 2,585 all type SE-related admissions (mean age = 58.6 years, SD = 24.7, 56.1% female) and 17,779 epilepsy-related admissions (mean age = 47.1 years, SD = 26.6, 48.4% female) were identified. Overall, 1,655 admissions (64%) were classified as NRSE, 592 (22.9%) as RSE, and 338 (13.1%) as SRSE (Table S1 ). Within the Gesundheitsforen Leipzig research database, using the study selection criteria, the total incidence of NRSE admissions was 15.0 in 100,000 per year, with RSE and SRSE incidence rates of 5.2 in 100,000 and 3.0 in 100,000 per year. The database incidence of all type SE was 23.2 in 100,000 per year. The database incidence rates for epilepsy were also calculated as a comparator. The age and gender distribution for admissions due to epilepsy, NRSE, RSE, and SRSE are shown in Table 1 .
The etiology of all type SE admissions identified by the algorithm was also examined. More than 40% of SE admissions (n = 1,153 SE admissions, 44.6%) had a previous history of epilepsy, 23.9% of SE admissions (n = 619) had no previous history of epilepsy, 24.8% (n = 640) of SE admissions were due to acute etiologies, and only a few admissions were classified as unclear (n = 110, 4.3%) or due to hypoxic brain injury (n = 63, 2.4%). In patients with an acute etiology, the main diagnoses were cerebral infarction (n = 99, 15.5%), infection-related (n = 88, 13.8%), tumorrelated (n = 58, 9.0%), intracerebral hemorrhage (n = 51, 8.0%), and intracranial injury (n = 37, 5.8%). Patients with NRSE, RSE, and SRSE also exhibited a wide range of comorbidities (Table S2) .
Hospital resource utilization
Median total length of stay per all type SE admission irrespective of SE severity was 11 days (mean = 21. 
Costs associated with SE
Median cost per all type SE admission irrespective of SE severity was €4,400 (mean = €11,563, SD = 30,537; Fig. 3 ). In detail, median admission cost was €4,063 (mean = €4,608, SD = 8,016) for NRSE, whereas RSE was associated with a median cost of €4,581 (mean = €9,219, SD = 15,356, p < 0.001) and SRSE was associated with a median cost of €32,706 (mean = €49,702, SD = 68,650, p < 0.001; Fig. 3 ). The cost details for all SE admissions by etiology are included in Fig. 3 . For the majority of admissions, an electroencephalogram (EEG; n = 1,757, 68.0%) and cerebral imaging were documented (Fig. 4) . When considering cerebral imaging modalities, computed tomography (CT; n = 1,621) was used in 62.7% of patients, and magnetic resonance imaging (MRI) was used in 28.4% of admissions (with contrast agent, n = 372 or 14.4%; without contrast agent, n = 362 or 14.0%). In SRSE, the documented fraction of EEG (n = 259, 76.6%), CT (n = 272, 80.5%), MRI with contrast agent (n = 73, 21.6%), and MRI without Female  74  61  27  73  70  16  64  65  6  Male  44  47  26  66  53  27  55  53  24  1  Female  60  55  26  65  60  23  67  63  18  Male  47  45  25  55  51  24  50  46  21  2  Female  80  71  24  76  74  12  74  66  19  Male  64  56  26  65  60  22  73  68  17  3  Female  76  68  22  73  66  23  71  65  18  Male  65  59  22  69  64  18  65  61  17  4  Female  73  60  35  73  73  12  74  66  18  Male  85  85  0  45  53  25  63  59 
Mortality and discharge disposition
Hospital mortality was determined as a percentage of encounters. Overall, the hospital mortality rate for all types of SE was 14.8% (Fig. 5) . Of those patients discharged alive, 8.9% were discharged to hospice care or a nursing home, 70.2% were discharged home, and 4.8% were discharged to a rehabilitation facility. In 1.2% of the patients, treatment was continued at another facility or was undefined (0.1%). Mortality increased from 9.6% in NRSE to 15.0% in RSE (p < 0.001) and to 39.9% in SRSE admissions (p < 0.001). Likewise, the fraction of patients discharged home decreased with increased SE severity, from 78.1% in NRSE to 70.1% in RSE (p < 0.001) to 31.7% in SRSE admissions (p < 0.001; Fig. 5 ).
Discussion
This study is the first large, population-based burden of illness study to evaluate health care costs, length of stay, and mortality associated with RSE and SRSE in Germany, and it is one of few studies to address the costs associated with SRSE. This study also confirms and highlights that SRSE is associated with significant morbidity and mortality.
The observed incidence rates of NRSE, RSE, and SRSE in the Gesundheitsforen Leipzig research database using the study algorithm trend toward the higher end of previously published estimates obtained from a broad range of sources and sites.
7,10,14-16,18,29-31 The higher incidence may reflect a number of different factors, including alignment with 32 Earlier studies required a seizure time of 30 min for an SE diagnosis, whereas more recent guidelines require only 5 or 10 min for generalized convulsive or nonconvulsive SE, respectively. 1 Notably, although the current study uses data collected before the 2015 changes in seizure duration, German guidelines adopted this standard in 2008. The definition of RSE has not changed, but based on the recent designation of SRSE and differing clinical assessments, it is likely that some RSE admissions are considered SRSE and vice versa. Overall, there may be variations in the application of diagnostic standards on a regional or national level that affect the assignment of NRSE, RSE, or SRSE. 11, 15 Incidence rates may also vary from country to country as a result of differences in the prevalence or rate of occurrence of the underlying conditions and disorders that cause NRSE, RSE, and SRSE; challenges in making an accurate diagnosis of NRSE, RSE, and SRSE, particularly in a patient population with multiple complications; limitations and variations in the diagnostic coding for these conditions; the small size of the populations studied in the literature; and differences and limitations in the analytical plans underlying the various published studies.
Notably, the determinations of an epilepsy syndrome versus SE based on ICD-9 or ICD-10 diagnoses in past studies and the present study are complicated by the mixture of seizure classifications within the classification of syndromes. Furthermore, the ICD-10 codes for epilepsy, epilepsy syndrome, and seizure may not directly correspond with the classifications historically defined by the ILAE or the most recently revised terminology and concepts for the organization of seizures and epilepsies. 25 Although SE has ICD-10 coding, the delineation between NRSE, RSE, and SRSE is not reflected by separate coding, so the definitions of etiology and severity of SE used in this study rely upon additional administrative data, primarily use of ventilation and ICU days. 25 In addition, ICD-10 and administrative coding may vary due to reimbursement pressures and regional/national differences in disease definition and coding used by physicians. 1, 11 The data also do not differentiate treatments for RSE or SRSE versus non-SE-related treatments. For instance, ventilation could be used for SRSE or for complications from SE, such as respiratory failure. Therefore, it is possible that by classifying based on diagnosis codes and ventilation time, some cases that are neither RSE or Figure 5 . Mortality and discharge destination rates for All status epilepticus (SE), nonrefractory SE (NRSE), refractory SE (RSE), and super-refractory SE (SRSE) admissions. Epilepsia ILAE SRSE could be classified as such based on complications requiring ventilation, introducing a small degree of bias into the analyses. However, in an earlier related study by Kortland et al. 33 that included chart reviews, only nine of 341 patients were ventilated for airway protection rather than as part of SE therapy (Strzelczyk, personal communication) . Although a strength of ICD-10 coding and administrative data analyses is the ability to examine large populations, they may lack the granularity of chart-level reviews of patients, including medication usage, which could impact assessments of diagnoses. Although the current study is only possible in such a large dataset, it remains limited by data protection guidelines that prohibit the analysis of chartlevel data to confirm diagnoses. This restriction on the ability to validate the analyses is common when using such retrospective claims data. Nonetheless, the results of our analyses are consistent with other recent retrospective studies of SE, RSE, and SRSE. 33, 34 The current analysis also does not utilize EEG data, which may be limited in many hospitals and is required to diagnose nonconvulsive SE, and the algorithm may also underrepresent less severe SE diagnoses, which may have less extensive coding associated with each visit, especially in NRSE or short SE durations < 30 min. Additionally, the primary coding for patients may reflect the underlying etiology instead of the SE diagnosis, resulting in further underrepresentation of SE.
Increased health care costs are observed with the progression from NRSE to RSE to SRSE. The overall mean cost for all types of SE admission was found to be €11,563 (median = €4,400, SD = 30,537). When further analyzed for the costs associated with NRSE, RSE, and SRSE, the mean costs were €4,608 (median = €4,063, SD = 8,016), €9,219 (median = €4,581, SD = 15,356), and €49,702 (median = €32,706, SD = 68,650) respectively, highlighting the high costs associated with SRSE treatment. Despite SRSE representing only 13% of SE admissions, SRSE contributed to 56% of all SE-related costs.
Although only a few studies have addressed the costs associated with SE, the two most recently published studies, using different methodologies, from the United States 32 and Germany 33 are in line with our results. Beg et al. 32 used a large claims database to analyze the health care resource utilization associated with SRSE in the United States. The study found a mean treatment cost of €45,741 (US $51,247) for SRSE patients, which is similar to the mean €49,702 (US $55,684) treatment cost observed in the present study. 32 However, the median length of stay of 11 days contrasts with the median length of stay of 37 days in the current study. Similar results for costs and length of stay of SRSE were described in a study by Kortland et al., with mean hospital costs of €50,488 and a mean length of stay of 37 days. Despite the similar outcomes observed, the Kortland study contrasts sharply in methodology, as it was conducted with a bottom-up approach, with detailed evaluations of each individual case. Although in line with our outcomes, this study also highlights the need for additional studies from larger databases for this rare condition. Despite a multicenter approach over 2 years, it only included 33 patients with SRSE. 33 In contrast with the current study, which examines a developed country, Misra et al. 35 investigated the cost of SE in India, revealing substantially different costs in a developing health care system. Other previous studies may not accurately reflect the current classification and treatment standards of SE, and they may use different payment systems. For instance, Penberthy et al. 36 first addressed the cost of SE in 2005, using data from 1993-1994 in the United States, prior to the implementation of current guidelines for NRSE, RSE, and SRSE.
Despite the differences in study methodologies, populations, and time periods, the costs reported in this study are similar to the costs observed in the Beg et al., 32 Kortland et al., 33 and Penberthy et al. 36 studies, when Penberthy is adjusted for inflation. Notably, the costs differ substantially from those calculated from a developing health care system. 35 Other differences across these studies may be due to national differences in prevalence of the various underlying conditions and disorders that cause SE (and their associated treatments), differences in analysis plans, challenges in making accurate diagnoses in complex patient populations, and small sample sizes.
For all SE classifications, the median total length of stay was 11 days (mean = 21.2 days, SD = 33.0). NRSE had the lowest length of stay (median = 8 days, mean = 13.6, SD = 16.1), with length of stay increasing in RSE (median = 14 days, mean = 23.4, SD = 16.1) and SRSE (median = 37 days, mean = 55.0, SD = 59.1). Thus, costs also directly correlated with the calculated median length of stay for NRSE, RSE, and SRSE, consistent with reports demonstrating that 85-90% of interpatient variability in ICU and post-ICU hospital costs could be attributed to length of hospital stay. 37 The higher costs of RSE and SRSE could also be attributed to the additional use of hospital resources and the high severity of the disease. A number of studies have shown that a higher severity of illness corresponds to higher ICU costs. 37, 38 This is consistent with the higher costs associated with RSE and SRSE, because these patients utilize mechanical ventilation and present with more severe symptoms.
SE that progresses to SRSE is associated with poor clinical outcomes, including high mortality rates. The overall mortality rate for SE of all types was 14.8%, ranging from 9.6% in NRSE to 15.0% in RSE and 39.9% SRSE, in agreement with previously published literature. 6, 16, 18 This study had several limitations, including that the data source is based on health insurance information, which does not include definitive chart level patient information, including medications, from medical records. The classifications of RSE and SRSE were based on a treatment-based algorithm, which is an imprecise tool. The classification of etiology may also overestimate de novo cases due to the examination of only 1 year of history prior to the index event. 39 Another limitation of the current cost analysis is the lack of longitudinal data on these patients. The study included information on discharge to home, rehabilitation, or other health care facilities, but the long-term costs incurred and the long-term outcomes at these additional locations were not captured. These additional costs could contribute substantially to the economic burden of SRSE, because only one-third of SRSE patients return to baseline, whereas the remainder are faced with neurological deficits. 6 Additionally, the broad applicability of the cost analysis is limited by the underlying etiologies of SE and comorbidities. Varying cerebrovascular and neurological disorders complicate the cost analysis associated with NRSE, RSE, and SRSE. The analysis was univariate, and no cohort matching was performed to allow cross-comparisons with similar etiologies and comorbidities. Finally, mortality was calculated based on patient encounter numbers, not individual patients, so mortality rates may be underestimates.
Conclusion
This study further highlights that SRSE is associated with high morbidity and mortality, and significant utilization of health care resources in Germany. Based on hospital admissions classified by the algorithm as SRSE, mortality was nearly 40%, and the mean cost of hospital care for SRSE admissions was €49,702. The high mortality, patient burden, and associated health care costs highlight the need for development of new treatment options for this disorder. Further studies should examine the burden of SRSE in other regions and datasets to understand the impact of SRSE in additional health care systems.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Table S1 . Incidence and secondary classifications (primary diagnosis, prior epilepsy history, and evidence of resuscitation) of SE, RSE, and SRSE. Table S2 . Top 10 comorbidities associated with status epilepticus.
